e-learning
resources
Paris 2018
Sunday, 16.09.2018
Innovative therapies in asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Methodology of clinical trials in COPD exacerbations: Eligibility criteria and endpoint selection.
A. Mathioudakis (Manchester, United Kingdom), M. Moberg (Hvidovre, Denmark), J. Janner (Hvidovre, Denmark), P. Alonso-Coello (Barcelona, Spain), J. Vestbo (Manchester, United Kingdom)
Source:
International Congress 2018 – Innovative therapies in asthma and COPD
Session:
Innovative therapies in asthma and COPD
Session type:
Poster Discussion
Number:
609
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Mathioudakis (Manchester, United Kingdom), M. Moberg (Hvidovre, Denmark), J. Janner (Hvidovre, Denmark), P. Alonso-Coello (Barcelona, Spain), J. Vestbo (Manchester, United Kingdom). Methodology of clinical trials in COPD exacerbations: Eligibility criteria and endpoint selection.. 609
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations
Source: ERJ Open Res, 5 (4) 00136-2019; 10.1183/23120541.00136-2019
Year: 2019
Discordant diagnostic criteria for pneumonia in COPD trials: a review
Source: Eur Respir Rev, 30 (162) 210124; 10.1183/16000617.0124-2021
Year: 2021
Introduction: Evaluation criteria in clinical trials involving patients suffering from COPD
Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease
Year: 2003
Limitations for the inclusion of patients in the Roflu-2011 study
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Classifying patients as GOLD A–D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials
Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Year: 2017
Dissociation between clinical trial inclusion and exclusion criteria for trials in severe asthma and the reality of the patient population
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
COPD therapy based on clinical phenotypes: Baseline data from the Czech multicentre research database of COPD
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
COPD severity analysis according to current evaluation criteria – National survey
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
Persistence of clinical criteria of chronic bronchitis in patients with COPD over time: A longitudinal analysis of the TRACE cohort.
Source: International Congress 2017 – Markers of COPD progression
Year: 2017
Roflumilast for stable COPD: Meta-analysis of randomized controlled trials
Source: International Congress 2014 – Clinical presentations
Year: 2014
Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data
Source: Eur Respir J 2014; 43: 842-851
Year: 2014
AUDIPOC: Spanish national clinical audit on COPD exacerbations. Results from the initial selection of cases
Source: Annual Congress 2009 - Epidemiology of COPD and infectious lung diseases
Year: 2009
Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials
Source: ERJ Open Res, 5 (2) 00072-2019; 10.1183/23120541.00072-2019
Year: 2019
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Recommendations of the ATS/ERS Task Force for the definition of outcomes for COPD pharmacological trials
Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers
Year: 2006
Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
The Spanish national clinical audit on COPD exacerbations (eCOPD). Pilot study: selection of study subjects
Source: Annual Congress 2008 - COPD in the elderly - quality of life and scores in COPD
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept